299432-99-8

Basic information

• Product Name: 1H-Indole, 6-bromo-1-[tris(1-methylethyl)silyl]-
• CAS NO: 299432-99-8
• Molecular Formula: C17H26BrNSi
• Molecular Weight: 352.39
• Mol File: 299432-99-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1H-Indole, 6-bromo-1-[tris(1-methylethyl)silyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole, 6-bromo-1-[tris(1-methylethyl)silyl]-(299432-99-8)
• EPA Substance Registry System: 1H-Indole, 6-bromo-1-[tris(1-methylethyl)silyl]-(299432-99-8)

Safety Data

• Hazardous Substances Data: 299432-99-8(Hazardous Substances Data)

Upstream product

• 52415-29-9 6-bromo-1H-indole 
• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 

Downstream Products

• 338969-77-0 2-(1-(triisopropylsilyl)-1H-indol-6-yl)-octahydro-1H-pyrido[1,2-a]pyrazine 
• 1144105-49-6 C₃₅H₄₅BrN₂O₂Si 
• 467461-44-5 6-phenylsulfonyl-1H-indole 
• 1403898-92-9 6-phenylsulfonyl-1-triisopropylsilanyl-1H-indole 
• 1423161-83-4 N-(2,4-dimethoxybenzyl)-3-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 
• 1423161-82-3 3-bromo-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 
• 1423160-82-0 C₂₃H₁₇F₃N₆O₃S₂ 
• 1423160-80-8 C₂₄H₂₁F₃N₆O₂S₂ 
• 1423160-78-4 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-1-methyl-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 
• 1423161-72-1 C₂₀H₁₅ClN₆O₂S₂ 
• 1423161-71-0 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 
• 321745-53-3 tert-butyl (2S)-2-[hydroxy(triisopropylsilyl-1H-indol-6-yl)methyl]pyrrolidine-1-carboxylate 
• 299433-10-6 2-(1-(naphthalen-1-ylsulfonyl)-1H-indol-6-yl)octahydropyrrolo[1,2-a]pyrazine 

Relevant articles and documents

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.